Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Abstract

Rates of response to a 12-week interferon-free combination regimen were more than 95% among previously treated patients with HCV genotype 1 infection, including patients with a prior null response. (Funded by AbbVie; SAPPHIRE-II ClinicalTrials.gov number, NCT01715415.).